Status:

COMPLETED

Defining Antibiotic Treatment Duration for Ventilator - Associated Lung Infection

Lead Sponsor:

University of Oxford

Collaborating Sponsors:

Medical Research Council

Department for International Development, United Kingdom

Conditions:

Ventilator Associated Pneumonia

Pneumonia, Bacterial

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

Intensive care units (ICUs), with high antibiotic consumption, are epicentres of antimicrobial resistance (AMR). Ventilator associated pneumonia (VAP) is the commonest hospital-acquired infection (HAI...

Eligibility Criteria

Inclusion

  • Patients 18 years and older
  • Invasive mechanical ventilation ≥ 48 hours
  • Satisfy the US Centers for Disease Control and Prevention National Healthcare Safety Network VAP diagnostic criteria
  • At least one of the following:
  • temperature \> 38 °C
  • white blood cell count ≥ 12,000 cells/mm3 or ≤ 4,000 cells/mm3
  • altered mental status with no other causes in \>70 year-olds; AND
  • Two or more chest imaging tests demonstrating at least one of the following:
  • new and progressive OR progressive and persistent infiltrate
  • new and persistent OR progressive and persistent consolidation
  • new and persistent OR progressive and persistent cavitation, AND
  • At least two of the following:
  • new onset of purulent sputum, or change in character of sputum, or increased respiratory secretions, or increased in suctioning requirements
  • new onset or worsening tachypnea or dyspnea
  • rales or bronchial breath sounds
  • worsening gas exchange defined by oxygen desaturations (e.g., PaO2/FiO2 \<240), increased oxygen requirements or increased ventilation demand

Exclusion

  • Poor likelihood of survival as defined by a Sepsis-related Organ Failure Assessment score (SOFA score) of \>11 points
  • Immunocompromised patients (HIV with CD4 \<200 cells/mm3, corticosteroids\> 0.5 mg/kg per day for \> 30 days, received chemotherapy in the past 3 months, solid organ or hematopoietic cell transplant)
  • Patients receiving antibiotic therapy for any other defined extra-pulmonary infections that warrant a duration of antibiotics longer than 7 days, or complications of pneumonia such as lung abscess or empyema, that warrant a duration of antibiotics longer than 7 days (excluding anti-tuberculosis treatment, antifungal medications, antibiotics meant for chronic suppression of chronic infections or chronic obstructive lung disease)
  • Patients who have been treated for VAP for more than 7 days from screening
  • Vulnerable population including prisoners and refugees

Key Trial Info

Start Date :

February 21 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 22 2023

Estimated Enrollment :

460 Patients enrolled

Trial Details

Trial ID

NCT03382548

Start Date

February 21 2018

End Date

March 22 2023

Last Update

January 18 2024

Active Locations (7)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (7 locations)

1

Civil Hospital

Kathmandu, Nepal

2

Patan Academy of Health Science, Patan Hospital, Kathmandu

Patan, Nepal

3

National University Hospital, Singapore

Singapore, Singapore

4

Tan Tock Seng Hospital

Singapore, Singapore